A completed reply can make an enquiry look finished. New patient information changes what needs to be assessed.
Pharmaceutical teams should ask for evidence that their intake process can handle that change.
At 16:00 on 1 October, the medical information response is complete.
An identifiable pharmacist had reported damaged foil and discoloured tablets in an unused pack of Medicine X, batch B123, and asked for the authorised storage conditions. No exposure or reaction had been reported.
Two days later, at 10:00, the pharmacist replies again. This time, the information describes an identifiable adult patient’s suspected reaction after using another pack of the same batch, with reported inpatient admission.
Every person, product, date and event in this example is fictional. All times are UTC. The operational question is concrete: what happens to that second message when the original medical information (MI) response is already marked complete?
Varun Sharma, founder at NEUVIOR, takes up the story.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
